Immunome Inc Strategic Asset Allocation Index
Immunome Inc strategic asset allocation index. Immunome Inc (IMNM) has a Strategic Asset Allocation Index of 12.9% as of June 2023. Strategic assets (PP&E of $1.20 Million plus long-term investments of $-) total $1.20 Million, measured against net assets of $9.34 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Immunome Inc to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Immunome Inc (2020–2022)
Strategic asset allocation index of Immunome Inc from 2020 to 2022. This chart shows how Immunome Inc's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of June 2023, the index stands at 12.9%, representing strategic assets of $1.20 Million against net assets of $9.34 Million USD. Check Immunome Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Immunome Inc Strategic Asset Allocation Index by Year (2020–2022)
Immunome Inc strategic asset allocation index by year from 2020 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Immunome Inc from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Immunome Inc stock valuation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 4.1% | $681.00K | $681.00K | $- | $16.65 Million | ▲ +2.3 pp |
| 2021 | 1.8% | $855.00K | $855.00K | $- | $48.19 Million | ▼ -1.9 pp |
| 2020 | 3.7% | $1.53 Million | $1.53 Million | $- | $41.34 Million | — |